Phase 2 N=154 Ciprofloxacin BioThrax Co-Administration Study
Anthrax
Primary: Ratios of Ciprofloxacin Area Under the Curve and Cmax (Day 5/Day 44) — 0.944; 0.887 ratio
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=5 Topical Interferon Gamma-1b for Central Serous Chorioretinopathy
Retinal Disease · Macular Disease
Primary: Total Number of Severe Ocular Adverse Events Related to the Investigational Product — 0 Adverse Events
Phase 2 N=834 Study of a Single Dose of Menactra® Vaccine 4-6 Years After Prior Menactra Vaccine
Meningitis · Meningococcal Infection
Primary: Number of Participants Achieving Antibody Titers ≥1:8 Against Meningococcal Serogroups A, C, Y, and W-135 by Serum Bactericidal Assay Using Human Complement Following…
Phase 2 N=259 Study of AC-201 in Patients With Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus
Primary: Change in HbA1c From Baseline — 0.03; -0.07; -0.13; 0.22 percentage points — p=0.044
Phase 2 N=37 Neutrophilic Asthma Study With Navarixin (MK-7123, SCH 527123) (MK-7123-017)(COMPLETED)
Neutrophilic Asthma
Primary: Number of Participants Who Maintained an Absolute Peripheral Blood Neutrophil Count >=1500/µL — 20; 12 Number of participants
Phase 2 N=27 Study Evaluating the Effects of IMA-638 on Allergen-Induced Airway Responses in Subjects With Mild Atopic Asthma
Asthma
Primary: Maximum Percent Drop From Pre-allergen Baseline in Forced Expiratory Volume in 1 Second (FEV1) for Late-Phase Asthma Response (LAR) at Screening — 27.19; 20.47 percent…
Phase 2 N=81 Efficacy, Tolerability, PK of OZ439 in Adults With Acute, Uncomplicated P.Falciparum or Vivax Malaria Mono-infection
Malaria, Falciparum · Malaria, Vivax
Primary: Derived Parasite Reduction Rate at 24 Hours (PPR24) — 1.38; 1.56; 1.71; 1.63 Log10 parasites/24h — p=0.01
Phase 2 N=84 Pharmacokinetics/Pharmacodynamics Biomarker Study in Active Ulcerative Colitis Patients
Colitis, Ulcerative
Primary: Fold Change From Baseline in Fecal Calprotectin at Week 14 — 0.41; 0.29; 0.79; 1.24 fold change — p=0.5320
Phase 2 N=15 Efficacy of Bucelipase Alfa (BSSL) in Patients With Cystic Fibrosis and Pancreatic Insufficiency
Cystic Fibrosis · Exocrine Pancreatic Insufficiency
Primary: The Absolute Difference Between Baseline and Treatment Coefficient of Fat Absorption (CFA) — 6.9 % CFA — p=0.2179
Phase 2 N=118 A Study to Compare CNTO 328 (Anti-IL-6 Monoclonal Antibody) and VELCADE-Melphalan-Prednisone (VMP) With VMP Alone in Previously Untreated Multiple Myeloma Patients
Multiple Myeloma
Primary: Percentage of Participants Who Achieved Complete Response (CR) - European Group for Blood and Marrow Transplantation (EBMT) Criteria — 22.4; 26.5 Percentage of…
Phase 2 N=100 Safety and Efficacy of LDV/SOF Fixed-Dose Combination (FDC) ± Ribavirin in HCV Genotype 1 Subjects
Chronic Hepatitis C Virus
Primary: Percentage of Participants With Sustained Virologic Response (SVR) at 12 Weeks After Discontinuation of Therapy (SVR12) — 95.0; 100.0; 94.7; 94.7 percentage of…
Phase 2 N=292 Open-Labeled Study of PSI-7977 and RBV With and Without PEG-IFN in Treatment-Naïve Patients With HCV GT2 or GT3
Chronic Hepatitis C Infection
Primary: Percentage of Participants Who Experienced Adverse Events — 10; 9; 10; 11 Percentage of participants
Phase 2 N=629 Efficacy and Safety of QMF149 vs. Salmeterol Xinafoate/Fluticasone Propionate in Patients With Chronic Obstructive Pulmonary Disease (COPD)
COPD
Primary: Mixed Model for Repeated Measures (MMRM): Between-treatment Comparisons for Trough FEV1 (L) on Day 85 — 1.270; 1.215; 1.277; 1.228 Liters
Phase 2 N=93 Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors
Gastrinoma · Glucagonoma · Insulinoma
Primary: Confirmed Response Rate — 10; 14 percentage of participants
Phase 2 N=60 Determine Effect of Enzalutamide (MDV3100) on the Androgen Signaling Pathway in Correlation With the Anti-tumor Effects of Enzalutamide
Metastatic Progressive Castration-resistant Prostate Cancer
Primary: Change From Baseline in Bone Marrow Testosterone — 0.05 ng/mL